These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 29093180)

  • 1. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study.
    Kiessling P; Lledo-Garcia R; Watanabe S; Langdon G; Tran D; Bari M; Christodoulou L; Jones E; Price G; Smith B; Brennan F; White I; Jolles S
    Sci Transl Med; 2017 Nov; 9(414):. PubMed ID: 29093180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.
    Smith B; Kiessling A; Lledo-Garcia R; Dixon KL; Christodoulou L; Catley MC; Atherfold P; D'Hooghe LE; Finney H; Greenslade K; Hailu H; Kevorkian L; Lightwood D; Meier C; Munro R; Qureshi O; Sarkar K; Shaw SP; Tewari R; Turner A; Tyson K; West S; Shaw S; Brennan FR
    MAbs; 2018 Oct; 10(7):1111-1130. PubMed ID: 30130439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic.
    Lledo-Garcia R; Dixon K; Shock A; Oliver R
    CPT Pharmacometrics Syst Pharmacol; 2022 Jan; 11(1):116-128. PubMed ID: 34735735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting the Effects of Anti-FcRn Therapy on the Disposition of Endogenous IgG in Humans.
    Li T; Balthasar JP
    J Pharm Sci; 2019 Jan; 108(1):714-724. PubMed ID: 30471293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells
    Qureshi OS; Sutton EJ; Bithell RF; West SM; Cutler RM; McCluskey G; Craggs G; Maroof A; Barnes NM; Humphreys DP; Rapecki S; Smith BJ; Shock A
    MAbs; 2024; 16(1):2300155. PubMed ID: 38241085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers.
    Yap DYH; Hai J; Lee PCH; Zhou X; Lee M; Zhang Y; Wang M; Chen X
    Clin Transl Sci; 2021 Sep; 14(5):1769-1779. PubMed ID: 33742786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.
    Ulrichts P; Guglietta A; Dreier T; van Bragt T; Hanssens V; Hofman E; Vankerckhoven B; Verheesen P; Ongenae N; Lykhopiy V; Enriquez FJ; Cho J; Ober RJ; Ward ES; de Haard H; Leupin N
    J Clin Invest; 2018 Oct; 128(10):4372-4386. PubMed ID: 30040076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses.
    Blumberg LJ; Humphries JE; Jones SD; Pearce LB; Holgate R; Hearn A; Cheung J; Mahmood A; Del Tito B; Graydon JS; Stolz LE; Bitonti A; Purohit S; de Graaf D; Kacena K; Andersen JT; Christianson GJ; Roopenian DC; Hubbard JJ; Gandhi AK; Lasseter K; Pyzik M; Blumberg RS
    Sci Adv; 2019 Dec; 5(12):eaax9586. PubMed ID: 31897428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.
    Nnane IP; Han C; Jiao Q; Tam SH; Davis HM; Xu Z
    Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):13-21. PubMed ID: 28132416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.
    Ling LE; Hillson JL; Tiessen RG; Bosje T; van Iersel MP; Nix DJ; Markowitz L; Cilfone NA; Duffner J; Streisand JB; Manning AM; Arroyo S
    Clin Pharmacol Ther; 2019 Apr; 105(4):1031-1039. PubMed ID: 30402880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.
    Robak T; Kaźmierczak M; Jarque I; Musteata V; Treliński J; Cooper N; Kiessling P; Massow U; Woltering F; Snipes R; Ke J; Langdon G; Bussel JB; Jolles S
    Blood Adv; 2020 Sep; 4(17):4136-4146. PubMed ID: 32886753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions.
    Getman KE; Balthasar JP
    J Pharm Sci; 2005 Apr; 94(4):718-29. PubMed ID: 15682382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial.
    Bril V; Benatar M; Andersen H; Vissing J; Brock M; Greve B; Kiessling P; Woltering F; Griffin L; Van den Bergh P;
    Neurology; 2021 Feb; 96(6):e853-e865. PubMed ID: 33219142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
    Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
    Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).
    Dall'Acqua WF; Kiener PA; Wu H
    J Biol Chem; 2006 Aug; 281(33):23514-24. PubMed ID: 16793771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.
    Proetzel G; Roopenian DC
    Methods; 2014 Jan; 65(1):148-53. PubMed ID: 23867339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
    Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
    MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FcRn Inhibitor Therapies in Neurologic Diseases.
    Alfaidi N; Karmastaji S; Matic A; Bril V
    CNS Drugs; 2024 Jun; 38(6):425-441. PubMed ID: 38724842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention.
    Patel DD; Bussel JB
    J Allergy Clin Immunol; 2020 Sep; 146(3):467-478. PubMed ID: 32896307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
    Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
    Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.